Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
For these efforts, RGC will utilize the Olink Explore HT platform and Ultima's UG 100 platform. Ultima's technology was selected for its scalability, efficiency, and suitability for large population-level studies requiring high-throughput data generation.
'We are pleased to continue supporting the ever-expanding large-scale proteomics studies that have the potential to drive important scientific and clinical insights,' said Gilad Almogy, founder and CEO of Ultima Genomics. 'These RGC proteomics studies build on the growing momentum we are seeing for population-scale proteomics and counting applications powered by Ultima's sequencing platform.'
About Ultima Genomics
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com
Ultima Media ContactVikki Herrera408-206-7009vikki@oakstreetcommunications.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
21 hours ago
- Malaysian Reserve
QuidelOrtho Launches Certified Analyzer Program
Initiative to expand testing access to underserved U.S. communities SAN DIEGO, Aug. 13, 2025 /PRNewswire/ — QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost. 'Our mission is rooted in equipping our customers so they can deliver diagnostic excellence to patients,' said Audra Jones, Senior Vice President, North America, QuidelOrtho. 'By repurposing and rigorously certifying high-performing analyzers, we aim to expand access to reliable diagnostic technology for healthcare facilities that play a critical role in their communities.' Each analyzer in the program undergoes a robust, multi-point certification process at QuidelOrtho's Rochester facility, including over 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. These analyzers undergo a comprehensive certification process to align with QuidelOrtho's established quality and performance criteria and include a 12-month warranty on service and support. The program features certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System. The VITROS platforms are designed to support community labs running general chemistries, immunoassay tests and drugs of abuse screening. 'We're proud to support healthcare providers who are the backbone of their communities, backed by our award-winning service and top-ranked customer satisfaction,' added Jones. 'This program isn't just about affordability; it's designed to improve accessibility and access of diagnostic solutions for healthcare providers in underserved communities.' QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit and follow QuidelOrtho on LinkedIn, Facebook and X. About QuidelOrtho Corporation QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day. Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic. Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions. Investor Contact: Juliet Cunningham Vice President, Investor Relations IR@ Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications Media@
Malaysian Reserve
a day ago
- Malaysian Reserve
Ultima Genomics' ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection
New bioRxiv paper showcases: Tumor-informed ctDNA detection down to one-in-ten million (10-7), which extends well beyond the limits of currently available clinical minimal residual disease (MRD) assays Superior double-stranded DNA (dsDNA) recovery rates versus other technologies, reducing sequencing requirements by 10- to 100-fold to achieve ultrasensitive detection levels and enabling a cost-effective whole-genome approach High efficiency and simple WGS workflow, yielding greater than 20x coverage per ng of cfDNA, reducing the amount of input material required for MRD and other liquid biopsy applications New highly sensitive approach to tumor-informed MRD as well as tumor-naive MRD and monitoring settings, where matched tumor tissue is not available FREMONT, Calif., Aug. 14, 2025 /PRNewswire/ — Ultima Genomics, a developer and manufacturer of an innovative ultra-high throughput sequencing architecture, announced a new publication, made available today in bioRxiv, showing the ultra-sensitive single-nucleotide variant (SNV) detection capabilities of its ppmSeq™ technology, with error rates down to 8 x 10-8. Led by researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center, this pre-print also demonstrates ctDNA detection limits for ppmSeq which significantly extends beyond the limits of currently available MRD assays, while utilizing a simple whole genome sequencing workflow that requires 10- to 100-fold less sequencing coverage versus other error correction techniques. These researchers conclude that these key features make ppmSeq well suited for clinical applications where high accuracy is required for mutation identification, such as tumor informed and tumor agnostic MRD detection. 'With its unique combination of low-cost and high accuracy, ppmSeq marks a real breakthrough in sequencing technology,' said Dan A. Landau, MD, PhD, a core member at the New York Genome Center, and Professor of Medicine & Professor of Physiology and Biophysics at Weill Cornell Medicine. 'It opens new horizons in studying the somatic genome as a novel frontier in human genetics, and holds enormous promise for clinical applications, including sensitive detection of cancer residual disease.' While high-throughput sequencing has seen rapid adoption for genome-wide variant identification, distinguishing true biological variation in the form of SNVs from sequencing errors remains a key challenge. Traditional sequencing approaches are too error-prone for detection of low variant allele frequency variants and are blind to errors resulting from DNA degradation or damage during sample preparation. These challenges limit the ability of traditional NGS technologies to detect and identify rare variants, a feature which is important in emerging applications like MRD and somatic mosaicism. To increase the ability to detect rare variants, current NGS approaches often rely on error-correction techniques, such as duplex sequencing, which involves sequencing both strands of a DNA molecule to filter out errors identified by discordant strands caused by single-stranded damage. While this reduces SNV error rates for dual-stranded reads, singleton reads must be discarded for these methods. As such, these methods require massive over sequencing to reliably capture sufficient duplex molecules, making whole-genome duplex sequencing prohibitively expensive. In a Nature Methods paper published in 2025, researchers in the Landau Lab demonstrated the advantages identifying SNVs with Ultima's flow-based sequencing by synthesis technology versus conventional SBS chemistry. Researchers identified that the ultra-low error profiles of Ultima's flow-based sequencing chemistry presented a foundation on which to build error correction techniques using duplex sequencing that could potentially enable ultra-low ctDNA detection levels, meaningful for applications that require rare mutation detection like MRD. In this new bioRxiv paper, researchers from the same group utilized ppmSeq, a technology developed by Ultima and native to the Ultima platform, to further improve upon the previously published low SNV detection limits. Building on Ultima's ultra-low error, flow-based sequencing, ppmSeq encodes both strands of DNA molecules in a single sequencing read to enable up to part-per-ten million (10-7) accuracy (SNVQ70) for SNV calling. This exceptional accuracy provides extreme assay sensitivity for low frequency alleles while also requiring 10- to 100-fold less sequencing depth than other error correction techniques. Study showcases ppmSeq as a highly accurate, low-cost, high throughput method for dsDNA sequencing built on a simple WGS workflow with potential for robust clinical applications Researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center benchmarked ppmSeq assay performance and sensitivity against other technologies. Key findings demonstrate ppmSeq has: Ultrasensitive SNV detection capabilities. ppmSeq demonstrated ultrasensitive SNV detection with error rates down to 0.8 x 10-7 (0.8 parts-per-ten million) for gDNA and cell-free DNA. Superior dsDNA recovery rates and lower sequencing requirements. ppmSeq demonstrated superior double-stranded DNA (dsDNA) recovery rates, reducing sequencing requirements by 10- to 100-fold and enabling a cost-effective whole genome approach. Ability to sequence low-input samples. The ppmSeq workflow was shown to be highly efficient, yielding greater than 20x coverage per ng of cfDNA and reducing the amount of input material required. Researchers also tested the capabilities of ppmSeq in clinical applications by assessing circulating tumor DNA (ctDNA) detection for disease monitoring in cancer patients. Key findings include: Tumor-informed ctDNA detection down to one-in-ten million. ppmSeq enabled tumor-informed ctDNA detection of 10-5 across multiple cancers, and up to 10-7 in cancers with high mutation burden at 30x sequencing depth, which extends below the limits of current MRD assays. ctDNA detection capabilities in tumor-naive disease monitoring. ppmSeq identified disease-specific signal in plasma cell-free DNA without the need for a matched tumor. Together, these researchers conclude that ppmSeq is a highly accurate and cost-effective option for emerging clinical applications including tumor-informed MRD, tumor-naïve MRD and an opportunity to explore new whole-genome applications in cancer genomics, including somatic mosaicism. 'As a highly accurate, highly scalable WGS approach, ppmSeq can be a key building block for the next generation of tumor-informed and tumor-naive cancer monitoring applications' said Adam Widman, MD, a researcher and medical oncologist at Memorial Sloan Kettering Cancer Center and a co-author on the study. 'ppmSeq is a major step forward in high-accuracy sequencing,' said Charles Swanton, Deputy Clinical Director at The Francis Crick Institute. 'Its low error rate and high throughput could enable powerful new applications in liquid biopsy and beyond. This study showcases how ultra-low error, high-throughput sequencing with ppmSeq could transform applications in the field of MRD requiring very high accuracy — from bench to bedside.' Ultima's ppmSeq technology enables high-quality data and its published specifications provide part-per-million accuracy, or SNVQ60, for calling single nucleotide variants (SNVs). ppmSeq, designed for the UG 100 sequencing platform, is also compatible with the UG 100 Solaris Free workflow. Launched at AGBT 2025, the UG 100 Solaris workflows enabled an over 50% increase versus prior specifications in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome. 'Ultima's unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications. It especially excels in applications like liquid biopsy that require extreme accuracy, and we are excited to see further validation of ppmSeq within the academic community,' said Gilad Almogy, CEO and Founder of Ultima Genomics. 'We believe that sensitivity, ease of workflow and low cost of ppmSeq will be transformational for applications requiring earlier detection such as MRD.' The full study, 'Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules' is now available in bioRxiv. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Media Contact Vikki Herrera for Ultima Genomics408-206-7009vikki@
Malaysian Reserve
a day ago
- Malaysian Reserve
FirstService Residential Earns WELL Certified™ Gold for South Region Headquarters
Company commemorates workplace excellence milestone with an immersive wellness event for associates in their South Region headquarters in Florida PLANTATION, Fla., Aug. 14, 2025 /PRNewswire/ — FirstService Residential, North America's leading residential property management company, announced today that its South Region headquarters has achieved WELL Certified™ Gold from the International WELL Building Institute. The recognition is awarded to spaces that prioritize health, safety, and well-being through measurable performance criteria and reflects FirstService Residential's commitment to cultivating employee-centered workplaces. To celebrate the milestone, the company hosted a wellness event yesterday, August 13, at its South Region headquarters. The day began with a live unveiling of the WELL Certified™ Gold seal by Debra George, Vice President of Operations of the company's South Region. In-person activities included chair yoga, sound bath sessions, nutrition education, tours, and a 'Build Your Own Healthy Bento Box' station for lunch. Each activation helped associates connect WELL principles to their daily routines in the office. 'Achieving WELL Certified™ Gold reflects our commitment to creating workplaces that support our associates' health and wellness,' said Robert G. Smith, President, South Region. 'This recognition underscores our belief that when our associates thrive in the workplace, they're better equipped to deliver exceptional support to the residents and communities we are proud to serve.' WELL Certification is based on attaining exceptional levels of quality in criteria including air and water quality, natural light, ergonomic workspace design, mental health support, and nutrition-focused amenities. This achievement reflects a shared effort between FirstService Residential and FirstService Energy, the company's energy advisory affiliate, to design a workplace that supports well-being in real, lasting ways. 'FirstService upholds the same wellness standards in our workspaces that we help residents and communities achieve in their homes,' said Paula Allen, Senior Vice President of Human Resources, South Region. 'Earning this certification required meeting strict criteria across all aspects of our work environment, which reflects the company's deep commitment to creating spaces where our team members can excel daily.' The WELL Certified™ Gold achievement adds to a growing list of workplace honors for FirstService Residential. The company was recently named to Newsweek's 2025 list of America's Greatest Workplaces for Mental Well-Being and earned repeated recognition from Great Place to Work® in the United States and Canada. These achievements reflect the company's belief that investing in associate well-being leads to stronger teams, better service, and thriving communities. About FirstService ResidentialFirstService Residential is simplifying property management. Its hospitality-minded teams serve residential communities across the United States and Canada. The organization partners with boards, owners, and developers to enhance the value of every property and the life of every resident. Leveraging unique expertise and scale, FirstService serves its clients with proven solutions and a service-first philosophy. Residents can count on 24/7 customer care and tailored lifestyle programming, amenity activation, and technology for their community's specific needs. Market-leading programs with FirstService Financial, FirstService Energy, and special districts teams deliver additional levels of support. Boards and developers select FirstService Residential to realize their vision and drive positive change for residents in the communities in their trusted care. FirstService Residential is a subsidiary of FirstService Corporation (NASDAQ and TSX: FSV), a North American leader in providing essential property services to a wide range of residential and commercial clients.
